Clinical trial · Interventional
GIST in Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation
Giving Information Strategically and Transparently in Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation
NCT03959046CI-TRIAL-00074053withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study has been withdrawn due to delays caused by COVID-19 and practical barriers to conducting the study.
Summary
Brief summary (as posted)
The purpose of this study is to assess the efficacy of using GIST language when speaking to patients about bone marrow and hematopoietic stem cell transplantation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Liquid Tumor | Liquid Tumor | ONTOLOGY_EXACT | 0.98 |
| Psychological Feedback | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GIST | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- GIST
- description
- GIST is an alternative way of speaking to patients. In order for patients to get the "gist," Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved.
- interventionNames
- Behavioral: GIST
- type
- NO_INTERVENTION
- label
- Usual Care
- description
- These are physician and patient participants that will communicate in their normal, unchanged way.
Primary outcomes (1)
- measure
- Change from 1 week post baseline understanding at 3 months
- timeFrame
- 1 week, 1 month and 3 months from baseline (T2, T3, and T4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * acute myeloid leukemia with high or intermediate risk in first complete remission acute myeloid leukemia OR myelodysplastic syndrome beyond first remission chronic myeloid leukemia with accelerated phase or blast crisis acute lymphocytic leukemia Myeloma lymphoma with a sensitive relapse lymphoma with a resistant relapse first time undergoing consultation at this institution's HSCT/BMT program Fluent in English Exclusion Criteria: * Cognitively impaired * Not fluent in English
References
Publications (0)
Data not yet available
No reference posted for this study.